glp-1 receptor agonists are contraindicated in transforming diabetes care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk when used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are Understanding GLP-1 receptor agonists and

Description

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Effectiveness of acupuncture as auxiliary combined with Western medicine for epilepsy: A systematic review and meta-analysis

(2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA